Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

C Baigent, Colin Baigent, Lisa Blackwell, Jonathan Emberson, L E Holland, Christina Reith, Neeraj Bhala, R Peto, Elizabeth H Barnes, Anthony Keech, John Simes
The Lancet
November 1, 2010
10.1016/s0140-6736(10)61350-5
Cited by 6,413Open Access
Full Text

Abstract

Related Papers

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
S. Féasson|The Lancet|2002|7k
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group|New England Journal of Medicine|1998|5.3k
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
Jeremiah Stamler, Olga Vaccaro, James D. Neaton et al.|Diabetes Care|1993|4.1k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter Sever, Björn Dahlöf, Neil R Poulter et al.|The Lancet|2003|3.8k
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators|New England Journal of Medicine|2006|2.9k